Bénédicte Menn
Investitore di Private Equity presso Oxford University Innovation Ltd.
Profilo
Bénédicte Menn founded Neurokin SA in 2003, where she worked as Project Leader from 2009 to 2014.
Dr. Menn also currently works at Oxford University Innovation Ltd., as Senior Investment Manager.
Dr. Menn received her undergraduate degree in 1990 from Ecole Nationale d'Administration.
Posizioni attive di Bénédicte Menn
| Società | Posizione | Inizio |
|---|---|---|
Oxford University Innovation Ltd.
 Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom. | Investitore di Private Equity | 01/01/2017 |
Precedenti posizioni note di Bénédicte Menn
| Società | Posizione | Fine |
|---|---|---|
Neurokin SA
 Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Fondatore | 11/03/2014 |
Formazione di Bénédicte Menn
| Ecole Nationale d'Administration | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Oxford University Innovation Ltd.
Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom. | Finance |
- Borsa valori
- Insiders
- Bénédicte Menn
